Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Did Amgen Waste $300 Million In Buying A Flawed Heart Drug?
Did Amgen Waste $300 Million In Buying A Flawed Heart Drug?
Did Amgen Waste $300 Million In Buying A Flawed Heart Drug?
Submitted by
admin
on October 12, 2015 - 1:39pm
Source:
Forbes
News Tags:
Amgen
Eli Lilly
evacetrapib
CETP inhibitors
Dezima
TA-8995
Headline:
Did Amgen Waste $300 Million In Buying A Flawed Heart Drug?
Do Not Allow Advertisers to Use My Personal information
